Eli Lilly and Company (LLY)
UndervaluedFundamental
69
मूल्य
$1157.08
मार्केट कैप
$1.05T
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Eli Lilly discovers, develops and sells prescription medicines, concentrating on diabetes and obesity, oncology, immunology and neuroscience. Its current growth is dominated by tirzepatide, the molecule sold as Mounjaro for diabetes and Zepbound for weight loss, which together now account for more than half of company revenue. Drugs reach patients through wholesalers, pharmacies and, increasingly, direct-to-consumer channels for the weight-loss franchise.
यह पैसा कैसे कमाती है
Revenue comes almost entirely from selling patented medicines at prices that reflect years of research and clinical-trial spending rather than manufacturing cost. A drug protected by patent can be priced with little direct competition; once patents expire, generic or biosimilar versions typically cut that product's sales sharply within a few years, which is why the pipeline behind today's bestsellers matters as much as the bestsellers themselves.
सेगमेंट के अनुसार राजस्व
Tirzepatide sold for type 2 diabetes, the single largest product and the fastest-growing major one in 2025.
The rest of the portfolio across diabetes, oncology, immunology and neuroscience, none individually broken out in the annual results.
The same molecule, tirzepatide, sold for chronic weight management — a newer indication already generating more than a fifth of total revenue.
A breast-cancer treatment and the largest product outside the tirzepatide franchise.
प्रतिस्पर्धी बढ़त (Moat)
पेटेंट और लाइसेंस · व्यापकPatents on approved molecules give Lilly years of protection from direct competition, and the regulatory approval process itself is a barrier few companies can clear. The tirzepatide franchise adds a manufacturing edge too: building the capacity to produce injectable GLP-1 drugs at this scale takes years, which is currently limiting how fast even a well-funded rival like Novo Nordisk can respond.
मांग को क्या चलाता है
डिफेंसिवMost of the portfolio treats chronic conditions — diabetes, cancer, autoimmune disease — that patients keep treating regardless of the economic cycle. The newer weight-loss business is more exposed to household budgets since much of it is paid out of pocket or with limited insurance coverage, but it still sits on top of an otherwise defensive base.
प्रमुख जोखिम
- Patent expiration and biosimilar competition — The company identifies the loss of intellectual-property protection on key products, and the entry of generic or biosimilar competitors once patents expire, as a risk to future revenue.
- Government and payer pricing pressure — Continued pricing pressure from governmental and private payers, including Medicare drug-price negotiation under U.S. law, affects pricing, reimbursement and patient access to Lilly's medicines.
- Concentration in a few products — The company depends on a relatively small number of products and a consolidated supply chain for a significant share of total revenue, so a manufacturing, safety or competitive setback for any one of them has an outsized effect.
खरीदने के पक्ष में तर्क
Buyers argue that the tirzepatide franchise still has years of volume growth ahead as obesity treatment expands globally, that manufacturing scale-up gives Lilly a lead over Novo Nordisk that is hard to close quickly, and that a broad pipeline beyond GLP-1 drugs reduces the company's dependence on any single therapeutic area.
बेचने के पक्ष में तर्क
Sellers fear that more than half of revenue now rests on one molecule facing well-capitalized competition and looming price cuts from Novo Nordisk, that government price negotiation will keep compressing margins on older products, and that a business this concentrated in a handful of drugs is unusually exposed to a single clinical, manufacturing or pricing setback.
Written by the editors, published on 18 अगस्त 2026
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
बैलेंस शीट और तरलता
राजस्व
$79.67B
पिछले 12 महीने (30/6/2026 तक)
शुद्ध आय
$26.71B
पिछले 12 महीने (30/6/2026 तक)
Free Cash Flow
-
कुल इक्विटी
$26.54B
कुल देनदारियाँ
$85.94B
Current Ratio
1.35
Interest Coverage
-
Debt/EBITDA
1.32
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$1551.10
वर्तमान मूल्य
$1157.08
Margin of Safety
+25.4%
Fair Value सीमा
$1030.42 - $2071.78
इस्तेमाल किए गए valuation methods के बीच का फैलाव, कोई सांख्यिकीय रूप से calibrated confidence interval नहीं।
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
38.83
ROE
77.8%
P/B Ratio
32.15
P/FCF
-
Gross Margin
83.4%
ROIC
-
लाभप्रदता Radar
मूल्य सृजन (प्रतिस्पर्धी बढ़त)
ROIC
-
WACC
7.7%
ROIC − WACC
-
Fundamental विश्लेषण मानदंड
पास (16)
- EPS shows upward trend
- Price CAGR 31.66%
- Gross Margin 83.4%
- Debt/Equity ratio
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 92.6%
- Revenue Growth 5Y 21.6%
- Analyst Consensus 79% Buy
- Earnings Surprise avg 24.8%
- PEG Ratio 1.51
- Earnings Quality (OCF/NI) 1.05
- Share Dilution -0.6%
- Net Margin Trend 33.5% vs 25.9%
- Piotroski F-Score 8/9
फेल (4)
- P/B Ratio 32.15
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Unknown)
अनुपलब्ध (7)
- ROIC NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Operating Margin NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
Piotroski F-Score
मजबूत वित्तीय स्वास्थ्य
Earnings गुणवत्ता
उच्च गुणवत्ता: earnings नकदी द्वारा समर्थित
शेयर Dilution
शेयर वापस खरीद रही है। शेयरधारक अनुकूल
संस्थागत होल्डिंग
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. David A. Ricks | Chairman, President & CEO | 57 |
| Mr. Lucas E. Montarce | Executive VP & CFO | 48 |
| Dr. Daniel M. Skovronsky M.D., Ph.D. | Chief Scientific & Product Officer and President of Lilly Research Laboratories | 52 |
| Ms. Anat Hakim J.D. | Executive VP, General Counsel & Secretary | 56 |
| Mr. Jacob S. Van Naarden | Executive VP, President of Lilly Oncology & Head of Corporate Business Development | 40 |
| Mr. Donald A. Zakrowski | Senior VP of Finance & Chief Accounting Officer | - |
| Mr. Diogo Rau | Executive VP and Chief Information & Digital Officer | 50 |
| Mr. Michael Czapar | Senior Vice President of Investor Relations | - |
| Mr. Eric Dozier | Executive VP & Chief People Officer | 58 |
| Mr. Ilya Yuffa | Executive VP and President of Lilly USA & Global Customer Capabilities | 50 |
Audit जोखिम
8
बोर्ड जोखिम
5
मुआवजा जोखिम
5
शेयरधारक अधिकार जोखिम
9
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
दस्तावेज़
- दस्तावेज़ देखें
वार्षिक रिपोर्ट (10-K)
कंपनी के कारोबार, वित्तीय नतीजों और जोखिमों का वार्षिक सिंहावलोकन।
दाखिल तिथि: 2026-02-12
- दस्तावेज़ देखें
तिमाही रिपोर्ट (10-Q)
पिछले तीन महीनों के वित्तीय प्रदर्शन का अपडेट।
दाखिल तिथि: 2026-08-05
- दस्तावेज़ देखें
विशेष रिपोर्ट (8-K)
किसी बड़ी घटना, जैसे नेतृत्व में बदलाव या बड़ी घोषणा, की सूचना।
दाखिल तिथि: 2026-08-05
via SEC EDGAR
आय का इतिहास
via SEC EDGAR
Latest News
Recent headlines for LLY, sourced from Markets Gazette.
- 16h agoNEUTRALAdding Lilly’s new drug to Zepbound helped people lose more weight — but there were more side effects
Eli Lilly's experimental amylin drug, when added to Zepbound, demonstrated increased weight loss in trials. However, this combination also led to a higher incidence of side effects. The company is exploring this drug's potential for both weight management and diabetes treatment. While the enhanced weight loss is a positive development, the increased side effect profile introduces a note of caution for investors. The net effect on the stock will likely depend on the severity and manageability of these side effects versus the efficacy gains.
- 13d agoPOSITIVELilly’s Newest Bull Says Near 300% Rally Is Only the Beginning
Eli Lilly and Company has experienced a remarkable surge of approximately 300% in its stock value over the past four years, following the approval of its first GLP-1 drug. This impressive performance has propelled the company's market capitalization beyond $1 trillion, establishing it as the preeminent pharmaceutical firm globally. The sustained growth trajectory, driven by its innovative GLP-1 treatments, suggests continued strong investor confidence and potential for further expansion in the lucrative obesity and diabetes markets. Analysts remain bullish, anticipating that this rally is far from over, indicating a robust outlook for the company.
- 29d agoPOSITIVELilly to Buy Merida for $2.88B in Autoimmune Push
Eli Lilly and Company has announced plans to acquire Merida Biosciences Inc. for up to $2.88 billion in cash. This strategic move aims to bolster Lilly's presence in the autoimmune and allergic diseases sector, diversifying its portfolio beyond its current dominance in weight-loss and diabetes treatments. The acquisition underscores Lilly's commitment to expanding its therapeutic reach and leveraging its financial strength to secure growth opportunities in promising medical fields. Investors may view this as a positive step towards sustained long-term growth and market leadership.
- 8/31/2026POSITIVELilly to Buy Merida for $2.88 Billion in Autoimmune Push
Eli Lilly and Company is set to acquire Merida Biosciences Inc. for up to $2.88 billion in cash, signaling a strategic expansion into autoimmune and allergic diseases. This move diversifies Lilly's portfolio beyond its highly successful weight-loss and diabetes drugs, Zepbound and Mounjaro. The acquisition is part of Lilly's aggressive deal-making strategy, with over $20 billion invested in 2026 alone, aimed at bolstering its pipeline with early-stage medicines to secure future blockbuster treatments. Investors may view this as a positive step towards sustained long-term growth and innovation.
- 8/12/2026NEGATIVEEli Lilly is suing pharmacies and peptide vendors over early sales of the next big weight-loss drug: retatrutide
Eli Lilly and Company has initiated legal action against pharmacies and peptide vendors accused of prematurely selling compounded versions of its upcoming weight-loss drug, retatrutide. This move aims to protect the integrity of its intellectual property and ensure the drug's eventual regulated release. The lawsuit highlights the intense market anticipation for retatrutide, a drug poised to be a significant player in the lucrative obesity treatment market. For investors, while the legal action may create short-term noise, it underscores Lilly's commitment to safeguarding its pipeline and maximizing the commercial potential of its innovative therapies.
- 8/11/2026POSITIVEEli Lilly Surges, Novo Nordisk Slips in Weight-Loss War
Eli Lilly and Company (NYSE:LLY) has reported a significant 48% surge in second-quarter revenue, reaching US$23 billion, driven by its blockbuster GLP-1 weight-loss and diabetes treatments. Sales of Mounjaro and Zepbound combined accounted for nearly 65% of total revenue, with Mounjaro alone seeing a 91% jump. The company has consequently raised its full-year revenue forecast to US$85-87 billion. This strong performance, coupled with a 7% stock increase in early trading, highlights Lilly's robust market position and growth potential in the highly competitive weight-loss drug sector, outperforming rivals like Novo Nordisk.
- 8/5/2026POSITIVELilly’s revenue soars 48%, driven by demand for its GLP-1s
Eli Lilly and Company reported a remarkable 48% surge in revenue, significantly exceeding expectations. This growth was primarily fueled by robust demand for its GLP-1 drugs, Mounjaro and Zepbound, which are indicated for Type 2 diabetes and weight loss respectively. The strong performance underscores the increasing market penetration and therapeutic success of Lilly's innovative treatments in high-demand areas. Investors will likely view this as a strong indicator of sustained future earnings growth and market leadership for the pharmaceutical giant.
via Markets Gazette